BioMarin Pharmaceutical. has filed a patent for prokaryotic PAL variants with enhanced phenylalanine-converting activity and reduced immunogenicity compared to wild-type PAL. The compositions can be used for treating hyperphenylalaninemia, including phenylketonuria, and other disorders like cancer. GlobalData’s report on BioMarin Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights BioMarin Pharmaceutical Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioMarin Pharmaceutical, Human telomerase RT biomarker was a key innovation area identified from patents. BioMarin Pharmaceutical's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

Phenylalanine ammonia-lyase variants for medical and industrial purposes

Source: United States Patent and Trademark Office (USPTO). Credit: BioMarin Pharmaceutical Inc

The patent application (Publication Number: US20240035013A1) discloses a pharmaceutical composition for treating phenylketonuria (PKU) comprising a pegylated Anabaena variabilis phenylalanine-ammonia lyase (AvPAL) variant with a specific amino acid sequence. The composition includes the pegylated AvPAL variant at concentrations ranging from 1 to 50 mg/mL, along with a pharmaceutically acceptable carrier containing NaCl, trans-cinnamic acid, Tris-HCl, L-phenylalanine (Phe), and glycine (Gly).

Furthermore, the patent application describes a method for treating individuals with PKU by administering the pharmaceutical composition to lower phenylalanine concentrations in the plasma. The method is effective for subjects with elevated plasma phenylalanine levels, with specific thresholds mentioned in the claims, and is particularly suitable for adult patients with PKU. The composition's pH range and specific concentrations of components in the carrier are also detailed to ensure optimal efficacy in treating PKU.

To know more about GlobalData’s detailed insights on BioMarin Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies